RxDoctor Payments Data

Carl Hyder, MD

Ophthalmology · Medford, NJNPI 1245371129

Payments from drug & device makers

$7,187in general payments, 2019–2025

Across 318 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • NEW World Medical,inc.$980
  • AbbVie$859
  • Sun Pharmaceutical Industries Inc.$698
  • Amgen$563
  • Lensar, Inc.$558
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,93196%
  • Education$1913%
  • Gifts$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,187 in reported general payments places this provider in the 85th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,604,321
Medicare patients
3,362
Services billed
13,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost198$113,065
RhopressaNetarsudil Mesylate196$79,263
RestasisCyclosporine76$63,379
XiidraLifitegrast29$42,624
VyzultaLatanoprostene Bunod57$28,842
Cyclosporine77$25,677
Latanoprost2,575$24,103
Brimonidine Tartrate152$23,558
XdemvyLotilaner12$22,480
Alphagan PBrimonidine Tartrate37$20,431
CequaCyclosporine22$17,138
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$15,603
Brinzolamide68$14,628
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat567$10,496
Prednisolone Acetate244$9,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$859$205,371345 claims
Aerie Pharmaceuticals, Inc.Rhopressa$57$79,263196 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$380$71,46686 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$54$22,48012 claims
Sun Pharmaceutical Industries Inc.Cequa$698$17,13822 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$106$7,92721 claims
AlconSimbrinza$1,033$5,53015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Medford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →